Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 9/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CD74 | P04233 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739936 | 0.92 | HTR6 (0.39) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| Trifluoroacetic Acid SCHEMBL744000 | 0.81 | HTR6 (0.34) | HTR6TRPA1CYP3A4HTR2CHTR2A | |
| Trifluoroacetic Acid SCHEMBL743674 | 0.80 | HTR6 (0.41) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| Trifluoroacetic Acid SCHEMBL742241 | 0.80 | HTR6 (0.50) | HTR6HTR2C | |
| Trifluoroacetic Acid SCHEMBL744092 | 0.80 | HTR6 (0.34) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| Trifluoroacetic Acid SCHEMBL743281 | 0.80 | HTR2C (0.37) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| Trifluoroacetic Acid SCHEMBL744076 | 0.79 | HTR6 (0.50) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| Trifluoroacetic Acid SCHEMBL743921 | 0.79 | HTR2C (0.47) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| Trifluoroacetic Acid SCHEMBL742666 | 0.79 | HTR6 (0.47) | HTR6HTR2C | |
| Trifluoroacetic Acid SCHEMBL743069 | 0.79 | HTR6 (0.49) | HTR6CYP3A4HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293694-A1 | New compounds | HTR6, HTR1A, HTR1B | BACE1 1082/4885HTR6 1/4885TRPA1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.